<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00809822</url>
  </required_header>
  <id_info>
    <org_study_id>NPB-01-06/E-01</org_study_id>
    <nct_id>NCT00809822</nct_id>
  </id_info>
  <brief_title>Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.</brief_title>
  <acronym>NPB-01</acronym>
  <official_title>NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(Phaseâ…¡).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nihon Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nihon Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients diagnosed with bullous pemphigoid were confirmed based on the investigators national&#xD;
      diagnostic criteria. Patients who meet all inclusion criteria and conflict the exclusion&#xD;
      criteria will receive NPB-01(intravenous immunoglobulin) 400mg/kg/day for five consecutive&#xD;
      days or Placebo(physiological saline). Subsequently, efficacy of NPB-01 for therapy of&#xD;
      bullous pemphigoid will evaluate using pemphigoid activity score involving skin lesion area&#xD;
      and Number of new blisters.&#xD;
&#xD;
      As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse&#xD;
      events by 57 days after the start of the study treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin lesion area (%), Number of new blisters/day, Pemphigoid Activity Score, Pemphigus Disease Area Index(PDAI), anti-BP180 and -BP230 antibody titers, Steroid dose, Time to escape from the protocol and its ratio</measure>
    <time_frame>57 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bullous Pemphigoid</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous immunoglobulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Physiological saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPB-01</intervention_name>
    <description>Intravenous immunoglobulin</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Physiological saline</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with corticosteroids over 20mg/day(Prednisolone) at informed consent.&#xD;
&#xD;
          2. Patients with continued treatment for bullous pemphigoid without add or change the&#xD;
             treatment after informed consent.&#xD;
&#xD;
          3. Patients who pemphigoid activity score is score1 and more before study medication&#xD;
             received.&#xD;
&#xD;
          4. Patients who symptom is not improve before study medication received.&#xD;
&#xD;
          5. Patients with twenty years old at informed consent.&#xD;
&#xD;
          6. Patients with hospitalization during five consecutive days of study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients treated with plasmapheresis at 28 days before informed consent.&#xD;
&#xD;
          2. Patients treated with corticosteroids pulse therapy(methylprednisolone over 0.5g/day)&#xD;
             at 14 days before informed consent.&#xD;
&#xD;
          3. Patients treated with intravenous immunoglobulin at 56 days before informed consent.&#xD;
&#xD;
          4. Patients who receive or adjust in increments immunosuppressants at 14 days before&#xD;
             informed consent.&#xD;
&#xD;
          5. Patients with malignancy or a history of this disease.&#xD;
&#xD;
          6. Patients with history of shock for NPB-01.&#xD;
&#xD;
          7. Patients with history of hypersensitivity for NPB-01.&#xD;
&#xD;
          8. Patients with IgA deficiency.&#xD;
&#xD;
          9. Patients with impaired liver function.&#xD;
&#xD;
         10. Patients with impaired renal function.&#xD;
&#xD;
         11. Patients with cerebro- or cardiovascular disorders.&#xD;
&#xD;
         12. Patients with high risk of thromboembolism.&#xD;
&#xD;
         13. Patients with hemolytic/hemorrhagic anemia.&#xD;
&#xD;
         14. Patients with decreased cardiac function.&#xD;
&#xD;
         15. Patients with decreased platelet.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>December 11, 2008</study_first_submitted>
  <study_first_submitted_qc>December 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2008</study_first_posted>
  <last_update_submitted>October 21, 2010</last_update_submitted>
  <last_update_submitted_qc>October 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Nihon Pharmaceutical Co., Ltd</name_title>
    <organization>Clinical Development Department</organization>
  </responsible_party>
  <keyword>IVIG in pemphigoid</keyword>
  <keyword>Patients with bullous pemphigoid unresponsive to corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemphigoid, Bullous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

